Can Some HER2-Positive Breast Cancer Patients Avoid Surgery?

Researchers tested whether certain patients with HER2-positive breast cancer may eventually be eligible for non-surgical management.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

We report a 76-year-old patient who was diagnosed with concurrent accessory breast and primary lung cancer, both were positive for somatic BRCA-2 (E1593D) mutation. He received concurrent radiation and platinum-based chemotherapy for lung cancer with good response, but breast cancer progressed in about 8 months, and further progressed after single agent anastrozole in 10 months. Next Generation Sequencing (NGS) of breast cancer was also positive forCCND1 (Cyclin D1) and FGFR1 amplifications. Despite a poor molecular profile of breast cancer, and progression following platinum-based chemotherapy and anastrozole, he was succ...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Late recurrence of estrogen receptor (ER) positive breast cancer is common. When tissues from a recurrent or metastatic focus are available, re-evaluation of ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) status is recommended for treatment selection. This case report describes a 59-year-old woman who underwent surgery for left breast cancer, with a histopathological diagnosis of invasive ductal carcinoma (pathological stage T2N1aM0 Stage IIB, ER positive, PgR positive and HER2 negative). A health check-up 16 years after surgery revealed multiple hepatic mass lesions, and the patient w...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
We describe the recent advances in clinical development of anti-HER2 treatments. To this aim, we used literature search via Pubmed and made an inventory of abstracts published during the last two years in major oncology conferences. Expert opinion: Further changes will probably occur during the next decade in the management of metastatic HER2-positive breast cancer. This is mainly driven by the fact that the two mainstay drugs (pertuzumab and TDM-1) that confer prolonged survival (56 months) to these patients are currently being used in the treatment of early-stage disease in a subset of patients. Thus, there is an urgent ...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Trastuzumab is an effective therapeutic treatment for Her2-like breast cancer; despite this most of these tumors develop resistance to therapy due to specific gene mutations or alterations in gene expression. Understanding the mechanisms of resistance to Trastuzumab could be a useful tool in order to identify combinations of drugs that elude resistance and allow a better response for the treated patients. Twelve primary biopsies of Her2+/hormone receptor negative (ER-/PgR-) breast cancer patients were selected based on the specific response to neoadjuvant therapy with Trastuzumab and their whole exome was sequenced leading...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Metastatic Breast Cancer Interventions:   Drug: Pyrotinib;   Drug: Treatment of physician's choice;   Drug: vinorelbine Sponsors:   Sun Yat-sen University;   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(Baylor College of Medicine) Researchers develop molecular testing to distinguish patients who may need less from those who may need more therapy for HER2 positive breast cancer.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Results seen for alpelisib plus fulvestrant in PIK3CA - mutated, HR + , HER2 − advanced breast cancer
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news
Following publication of the original article [1], the authors reported the following errors in the article.
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Correction Source Type: research
Publication date: Available online 22 June 2019Source: Journal of Geriatric OncologyAuthor(s): Etienne Brain, Philippe Caillet, Nienke de Glas, Laura Biganzoli, Karis Cheng, Lissandra Dal Lago, Hans WildiersAbstractHER2-positive (HER2+) breast cancer (BC) affects older women nearly as frequently as younger ones. Many older patients have cardiovascular comorbidity and risk greater toxicity from therapy. Treatment therefore requires careful consideration, especially since trials include few patients over 65 and so provide limited guidance. A multidisciplinary task force of the International Society of Geriatric Oncology cond...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Objectives: The contribution of tumor subtypes (TS) in each stage of breast cancer with the use of contemporary therapies is unclear. The aim of this study was to analyze differences in overall survival (OS) by TS according to stage compared with other factors. Materials and Methods: We evaluated women with breast cancer diagnosed between 2010 and 2013 with known estrogen receptor and progesterone receptor (together hormone receptor [HR]) status and human epidermal growth factor receptor 2 (HER2) status reported to the SEER program. Patient characteristics were compared between TS. Univariate and multivariate analyses...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Breast Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2